You're browsing as a guest. Sign in to unlock all features.

CER

CER·Biotechnology·United States

CER is involved in the development and commercialization of innovative therapies aimed at addressing significant unmet medical needs in the healthcare sector. Sector: Healthcare | Industry: Biotechno...

1 Total1 External0 In-site
CERCER
2026-04-02
🏥 HealthcarePitch
Externalby Norbury Capital · Other

Norbury Capital on CER (CER)

公司名称:Cerillion

主要经营地:英国

详细生意模式:电信BSS/OSS软件供应商,提供成本有效的SaaS vs 昂贵的遗留系统(Amdocs, Netcracker)。核心产品用于电信运营商的计费、充值和客户管理。最近赢得£47M Omantel合同(>FY revenue),管线显示5+更大规模的投标即将到来。交易11x EV/EBITDA FY27E尽管缩放至更大交易,液流小盘英国股票

护城河:🟢强:Amdocs/Netcracker替代品定位强+成本优势+大合同赢得能力+TM Forum Diamond认证

估值水平:EV/EBITDA 15.9x (FY26E 11x), FCF Yield 4.2%

EV/Market Cap:EV $349M / MC $380M

网络观点:作者指出CER.L赢得£47M Omantel合同(超FY revenue),管线显示5+更大规模投标机会。交易成本有效的BSS/OSS替代品定位,远低于Amdocs/Netcracker。FY27E EV/EBITDA仅11x提供增长选项

AI观点:CER.L Omantel赢利显示产品竞争力,但液流风险在AIM上股份较少。网络搜索显示CER在MWC Barcelona 2026推广战略动力,达成TM Forum Diamond Open API认证(50+已认证API)。新AI账单系统也推出。关键风险:①Lumpy deal flow(大合同依赖性);②AIM流动性;③Amdocs/Oracle等大型竞争对手的价格战。结论:值得深入研究,中等风险但增长潜力可观